Hypoxia Signaling in Cancer: From Basics to Clinical Practice.
Hypoxia Signaling in Cancer: From Basics to Clinical Practice.
复制标题
DOI:
10.3389/pore.2021.1609802
复制
发表时间:
2021
期刊:
影响因子:
--
通讯作者:
Tímár J
中科院分区:
文献类型:
--
作者:
Sebestyén A;Kopper L;Dankó T;Tímár J
Cancer hypoxia, recognized as one of the most important hallmarks of cancer, affects gene expression, metabolism and ultimately tumor biology-related processes. Major causes of cancer hypoxia are deficient or inappropriate vascularization and systemic hypoxia of the patient (frequently induced by anemia), leading to a unique form of genetic reprogramming by hypoxia induced transcription factors (HIF). However, constitutive activation of oncogene-driven signaling pathways may also activate hypoxia signaling independently of oxygen supply. The consequences of HIF activation in tumors are the angiogenic phenotype, a novel metabolic profile and the immunosuppressive microenvironment. Cancer hypoxia and the induced adaptation mechanisms are two of the major causes of therapy resistance. Accordingly, it seems inevitable to combine various therapeutic modalities of cancer patients by existing anti-hypoxic agents such as anti-angiogenics, anti-anemia therapies or specific signaling pathway inhibitors. It is evident that there is an unmet need in cancer patients to develop targeted therapies of hypoxia to improve efficacies of various anti-cancer therapeutic modalities. The case has been opened recently due to the approval of the first-in-class HIF2α inhibitor.
登录
查看更多内容
影响因子:
5.2
作者:
Ghimessy, Aron Kristof;Gellert, Aron;Dome, Balazs
通讯作者:
Dome, Balazs
影响因子:
11.2
作者:
Dome, Balazs;Timar, Jozsef;Tovari, Jozsef
通讯作者:
Tovari, Jozsef
影响因子:
6
作者:
Dezso, Katalin;Bugyik, Edina;Paku, Sandor
通讯作者:
Paku, Sandor
影响因子:
4.7
作者:
Benej, Martin;Svastova, Eliska;Pastorekova, Silvia
通讯作者:
Pastorekova, Silvia
影响因子:
2.8
作者:
Burian, Z.;Ladanyi, A.;Timar, Jozsef
通讯作者:
Timar, Jozsef